The Kinghorn Cancer Centre
Welcome,         Profile    Billing    Logout  
 0 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kent, Robert
ACTRN12618001074280: Intervention study assessing the novel use of seviteronel in androgen receptor positive cancers

Recruiting
2
16
 
St Vincent's Hospital, Innocrin Pharmaceuticals Inc
Solid cancers
 
 
WinPro, NCT03906669: A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.

Recruiting
2
200
RoW
Letrozole, Letrozole and Prometrium, Tamoxifen and Prometrium
St Vincent's Hospital
Early-stage Breast Cancer, Hormone Receptor Positive Tumor
04/24
04/24
NADOM, NCT05187884: Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma

Active, not recruiting
2
15
RoW
Darovasertib
Anthony Joshua, FRACP, St Vincent's Hospital, Sydney
Ocular Melanoma
11/24
11/25
ANZUP 1903, NCT04918810: Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer

Terminated
2
6
RoW
Docetaxel intermittent
Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Peter MacCallum Cancer Centre, Australia
Castration Resistant Prostatic Cancer
11/24
11/24
PICASSO, NCT04925648: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction

Recruiting
2
22
RoW
Dasatinib, Darolutamide
St Vincent's Hospital, Sydney
Metastatic Prostate Cancer
12/24
06/25
HiTeCH, NCT03522064: Bipolar Androgen Therapy + Carboplatin in mCRPC

Recruiting
2
30
RoW
Testosterone Enanthate 100 MG/ML Injectable Solution, Primoteston Depot, Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5
St Vincent's Hospital, Sydney
Castration-resistant Prostate Cancer, Homologous Recombination Deficiency
12/24
12/25
NCT05608876: A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

Recruiting
2
37
Europe, RoW
Tigilanol Tiglate, EBC-46
QBiotics Group Limited
Head and Neck Cancer
08/25
10/26
TICTOC, NCT05156892: Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer

Recruiting
1/2
44
RoW
SUBA-itraconazole, Tamoxifen
Anthony Joshua, FRACP, Royal Prince Alfred Hospital, Sydney, Australia, Concord Hospital, Prince of Wales Hospital, Sydney, St Vincent's Hospital, Sydney
Ovarian Cancer
01/24
01/25
Gallagher, Richard
NCT05608876: A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

Recruiting
2
37
Europe, RoW
Tigilanol Tiglate, EBC-46
QBiotics Group Limited
Head and Neck Cancer
08/25
10/26

Download Options